全文获取类型
收费全文 | 3385046篇 |
免费 | 252186篇 |
国内免费 | 5018篇 |
专业分类
耳鼻咽喉 | 47167篇 |
儿科学 | 111098篇 |
妇产科学 | 93832篇 |
基础医学 | 491710篇 |
口腔科学 | 96801篇 |
临床医学 | 305958篇 |
内科学 | 649201篇 |
皮肤病学 | 74112篇 |
神经病学 | 270127篇 |
特种医学 | 129202篇 |
外国民族医学 | 902篇 |
外科学 | 508923篇 |
综合类 | 76490篇 |
现状与发展 | 13篇 |
一般理论 | 1299篇 |
预防医学 | 267274篇 |
眼科学 | 79316篇 |
药学 | 253624篇 |
13篇 | |
中国医学 | 6359篇 |
肿瘤学 | 178829篇 |
出版年
2018年 | 35772篇 |
2017年 | 27245篇 |
2016年 | 30533篇 |
2015年 | 34721篇 |
2014年 | 48783篇 |
2013年 | 73904篇 |
2012年 | 101075篇 |
2011年 | 107341篇 |
2010年 | 63771篇 |
2009年 | 60480篇 |
2008年 | 101336篇 |
2007年 | 107746篇 |
2006年 | 108943篇 |
2005年 | 106001篇 |
2004年 | 102523篇 |
2003年 | 98202篇 |
2002年 | 95838篇 |
2001年 | 151204篇 |
2000年 | 155954篇 |
1999年 | 131879篇 |
1998年 | 38345篇 |
1997年 | 33979篇 |
1996年 | 33965篇 |
1995年 | 32494篇 |
1994年 | 30203篇 |
1993年 | 28512篇 |
1992年 | 105524篇 |
1991年 | 103172篇 |
1990年 | 100779篇 |
1989年 | 97394篇 |
1988年 | 90171篇 |
1987年 | 88527篇 |
1986年 | 83708篇 |
1985年 | 80628篇 |
1984年 | 60450篇 |
1983年 | 51847篇 |
1982年 | 30773篇 |
1981年 | 27747篇 |
1979年 | 56805篇 |
1978年 | 40222篇 |
1977年 | 33744篇 |
1976年 | 32147篇 |
1975年 | 34381篇 |
1974年 | 41601篇 |
1973年 | 39786篇 |
1972年 | 37135篇 |
1971年 | 35072篇 |
1970年 | 32345篇 |
1969年 | 30732篇 |
1968年 | 28097篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
994.
J. Saßmannshausen N. Bornfeld A. Kluge W. Sauerwein F. Härting A. Wessing 《International ophthalmology》1989,13(4):243-251
Advanced malignant melanomas of the uvea unsuited for an eye salvaging approach require enucleation of the tumor containing eye. A series of 68 patients is reported who underwent enucleation combined with insertion of a spherical dura-encased implant after 30 Gray pre-irridiation therapy of the orbit. Postoperative results with special attention to cosmetic outcome and motility of the prosthesis suggest that the insertion of an orbital implant should be preferred to the enucleation with no implant. 相似文献
995.
Fatal and non-fatal stingray envenomation 总被引:2,自引:0,他引:2
A fatality occurred in a previously healthy 12-year-old boy after a penetrating chest injury from a stingray barb. The injury occurred under freak circumstances. Death was a result of cardiac tamponade which was secondary to venom-induced, localized myocardial necrosis and spontaneous perforation, six days after the direct penetration of the right ventricle by the barb. Three other cases of less serious stingray envenomation are described which illustrate the significant localized morbidity that may occur without immediate wound exploration and toilet after adequate anaesthesia. We also report a study of a series of 100 minor stingray envenomations which, when treated, resulted in no morbidity. It is possible that local infiltration with 1% plain lignocaine may have a direct counteraction against stingray venom that remains in the wound area. Stingray venom has insidious, but powerful, localized tissue necrosing properties in humans. 相似文献
996.
997.
Dihydroxyacetone (DHA), a browning agent, protects photosensitive rats and humans against long ultraviolet radiation (UVA, 320-400 nm) and visible (blue) light. The photoprotective efficacy of DHA and structurally similar compounds was assessed as prevention of edema in the paws of psoralen-sensitized rats, after exposure to blacklight fluorescent lamps. Methylglyoxal produced a yellow-brown color and provided nearly the same protection as DHA, whereas monohydroxyacetone did not color the skin and afforded little or no protection. Glyceraldehyde provided a moderate amount of protection, which was enhanced by prior exposure of the agent to alkaline pH. A solution of 5-hydroxymethylfurfuraldehyde was yellow and provided minimal protection by staining the skin rather than browning it. We conclude that the ability to produce a brown color in skin is a useful criterion for screening compounds for photoprotective efficacy against UVA radiation. 相似文献
998.
A long-term clinical and therapeutic study was performed in 47 patients with mesangial IgA glomerulonephritis. The male to
female ratio was 2.9∶1. An episode of gross haematuria or the incidental discovery of asymptomatic microscopic haematuria
with associated mild proteinuria heralded the apparent onset of renal disease. At the onset of observation 18 patients (38.2%)
had high blood pressure. Other 17 patients developed hypertension during observation. Anaemia was uncommon. No essential abnormalities
in serum protein and lipid patterns were found. Twenty-nine patients (61.6%) had higher levels of serum immunoglobulins—most
frequently of IgA (42.5%). Twenty-two patients had low serum C3 levels (46.8%). The percentage of patients with renal failure increased from 21.2 to 36.1 during observation. Male sex, hypertension,
proteinuria higher than 2 g/24 h, elevated ESR, high serum IgA levels, longer duration of the disease and older age of patients
suggest an unfavourable outcome. Long-term treatment with a combination of azathioprine/acenocumarol, or indomethacin, or
levamisole has no effect on the clinical manifestation and evolution. 相似文献
999.
In a prospective study 90 patients who had confirmed abruption of the placenta were compared with a control group. Significantly more patients who had abruptio placentae were unmarried, smoked cigarettes, received no antenatal care, had coitus within the 48 hours preceding delivery, developed intrapartum hypertension and had a lower ponderal index than the controls. More patients with abruptio placentae had proteinuria and antepartum hypertension but statistical significance was not reached. In addition, the incidence of intra-uterine growth retardation was higher in these patients. 相似文献
1000.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献